Exendin-4 for Parkinson's disease

This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Esparza-Salazar, Felipe de Jesús, Lezama-Toledo, Alma Rosa, Rivera-Monroy, Germán, Borlongan, Cesario V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057099/
https://www.ncbi.nlm.nih.gov/pubmed/34084977
http://dx.doi.org/10.4103/bc.bc_21_21
Descripción
Sumario:This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.

Ejemplares similares